Community Member
8 months agoHas anyone’s doctor unilaterally changed herceptin brand with hercessi, a recently fda approved bio similar drug ?
Accepted Answer
Switching from Herceptin to Hercessi is becoming more common as healthcare systems adopt biosimilar medications. Many patients in the HER2+ community have experienced similar changes, often without advance notice from their medical teams. This transition can understandably feel concerning when it happens without discussion. Consider reaching out to your oncology team to understand their reasoning and to address any questions about the switch - they can provide specific information about efficacy and monitoring protocols for biosimilars in your treatment plan.
3+ patients found this helpful
Community Member
6 months agoI could see this happening if there was an insurance change and Herceptin was no longer covered. My insurance wouldn’t cover Herceptin and I was on a biosimilar instead.
Community Member
6 months agoDid you notice any difference ? I’m apprehensive given that they contracted with a new bio similar
Community Member
6 months agoI was only on the biosimilar. There are several biosimilars for Herceptin. Not really sure what differences there are. I would ask your doctor why they picked that particular one.
Community Member
6 months agoCheaper cost for insurance
Community Member
6 months agoI’m on Kanjenti biosimilar to Herceptin. Same reason…cost. I’ve been lucky so far with no issues. Going on 5th dose, so time will tell. I need to take it for a year, 21 days apart. Along with Perjeta.
Community Member
6 months agoSame here , since it was switched mid treatment , I’ve experienced stronger bouts of non stop diarrhea, exhausting !
Community Member
2 months agoSwitching from Herceptin to Hercessi is becoming more common as healthcare systems adopt biosimilar medications. Many patients in the HER2+ community have experienced similar changes, often without advance notice from their medical teams. This transition can understandably feel concerning when it happens without discussion. Consider reaching out to your oncology team to understand their reasoning and to address any questions about the switch - they can provide specific information about efficacy and monitoring protocols for biosimilars in your treatment plan.
New to the community?
Create an account to connect with others navigating cancer.
© 2025 Outcomes4Me Inc. All rights reserved.